Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00129805
Status:
COMPLETED
Last Update Posted:
2008-08-19
First Post:
2005-08-11
Brief Title:
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction S-ACCESS
Sponsor:
Mitsubishi Tanabe Pharma Corporation
Organization:
Mitsubishi Tanabe Pharma Corporation
Study Overview
Official Title:
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction S-ACCESS A Randomized Double-Blind Aspirin-Controlled Trial
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sarpogrelate MCI-9042 is an antiplatelet drug that decreases 5-hydroxytryptamine 5-HT levels in platelets via a blockade of 5-HT2 receptors it has been used in atherosclerotic peripheral arterial disease
S-ACCESS was a randomized double-blinded trial to compare the relative efficacy of sarpogrelate 100mg three times daily and aspirin 81mg once daily in 1510 patients with recent cerebral infarction Patients were followed for 09 to 35 years The primary endpoint was recurrence of cerebral infarction relative safety was also assessed
S-ACCESS was a randomized double-blinded trial to compare the relative efficacy of sarpogrelate 100mg three times daily and aspirin 81mg once daily in 1510 patients with recent cerebral infarction Patients were followed for 09 to 35 years The primary endpoint was recurrence of cerebral infarction relative safety was also assessed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None